Microbot Medical INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Microbot Medical Inc. reports FDA clearance for its LIBERTY Endovascular Robotic Surgical System and initiates limited market release, while continuing to incur significant operating losses and requiring additional funding.
NASDAQ
Microbot Medical's 10-K filing highlights the company's continued operating losses, its strategic focus on the LIBERTY Endovascular Robotic Surgical System, and recent capital raising activities to support its operations.
NASDAQ
Microbot Medical Inc. released its 2023 annual report, detailing financial results and progress on its LIBERTY robotic surgical system.